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Relaxin is a peptide hormone with anti-ﬁbrotic properties. To investigate the long-term effects of relaxin deﬁciency
on the ageing skin, we compared structural changes in the skin of ageing relaxin-deﬁcient (RLX/) and normal
(RLXþ /þ ) mice, by biochemical, histological, and magnetic resonance imaging analyses. Skin biopsies from
RLXþ /þ and RLX/ mice were obtained at different ages and analyzed for changes in collagen expression and
distribution. We demonstrated an age-related progression of dermal ﬁbrosis and thickening in male and female
RLX/ mice, associated with marked increases in types I and III collagen. The increased collagen was observed
primarily in the dermis of RLX/ mice by 1 mo of age, and eventually superseded the hypodermal layer. Ad-
ditionally, ﬁbroblasts from the dermis of RLX/ mice were shown to produce increased collagen in vitro. Re-
combinant human gene-2 (H2) relaxin treatment of RLX/ mice resulted in the complete reversal of dermal
ﬁbrosis, when applied to the early onset of disease, but was ineffective when applied to more established stages of
dermal scarring. These combined ﬁndings demonstrate that relaxin provides a means to regulate excessive col-
lagen deposition in disease states characterized by dermal ﬁbrosis and with our previously published work dem-
onstrate the relaxin-null mouse as a model of progressive scleroderma.
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Scleroderma or systemic sclerosis is a complex, chronic
connective tissue disease, which primarily causes skin
thickening and hardening in addition to interstitial fibrosis of
various internal organs (lung, heart, kidney, gastrointestinal
tract, blood vessels, etc) (Denton and Black, 2000; Simms
and Korn, 2002; Kissin and Korn, 2003). The associated
fibrosis is potentially driven by several independent factors
involving immunological disorders, enhanced workload,
hypertrophy, injury-repair mechanisms or metabolic de-
fects, which eventually leads to the proliferation and differ-
entiation of matrix-producing fibroblasts. Stimulated by a
number of cytokines and growth factors, these cells differ-
entiate into myofibroblasts and synthesize prodigious
amounts of matrix proteins, mainly collagen, leading to tis-
sue scarring and thickening (Korn, 2002). Although the
symptoms of scleroderma vary between individuals, it can
develop in every age group and if not properly treated, can
lead to irreversible tissue damage.
Given that scleroderma offers many targets for therapy,
several agents have been used to treat various aspects of
the disease (Denton and Black, 2000; Mouthon and Agard,
2001; Korn, 2002; Simms and Korn, 2002), including vaso-
dilators, anti-inflammatory drugs and inhibitors of growth
factors, intercellular signalling, gene transcription, collagen
production and matrix synthesis pathways; however, many
have been limited in their application, whereas others inhibit
several mechanisms and are non-specific.
Relaxin is a small dimeric peptide hormone with known
anti-fibrotic and vasodilatory properties (Samuel et al,
2003a; Sherwood, 2004). Although generally associated
with female reproductive tract physiology (Sherwood,
2004), relaxin has also been shown to inhibit fibroblast
function (Samuel et al, 2004a), decrease collagen secretion
(Unemori and Amento, 1990; Unemori et al, 1993, 1996;
Garber et al, 2001; Williams et al, 2001; Samuel et al,
2004a), increase matrix metalloproteinase expression and
inhibit the influence of several pro-fibrotic factors to induce
a matrix-degrading phenotype in several non-reproductive
organs and cells (reviewed in Gavino and Furst, 2001;
Sherwood, 2004). Relaxin acts directly on transforming
growth factor (TGF)-b-stimulated human dermal fibroblasts
(Unemori and Amento, 1990; Samuel et al, 2003b) and on
human scleroderma fibroblasts (Unemori et al, 1992) to de-
crease collagen, fibronectin, and fibrillin-2 overexpression.
Relaxin was also shown to decrease collagen accumulation
in several rodent models of fibrosis (Unemori et al, 1996;
Garber et al, 2001; Williams et al, 2001; Samuel et al,
2004a), including two rodents models of dermal fibrosis
(Unemori et al, 1993). These relaxin-induced effects on ma-
trix turnover are species independent, but are most likely
influenced by organ-specific factors.
Abbreviations: H2, human gene-2; HDF, human dermal fibroblasts;
MRI, magnetic resonance imaging; RLX/, relaxin deficient;
RLXþ /þ , relaxin normal
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We have used gene-targeting means to establish a re-
laxin gene-knockout (RLX/) mouse that lacks the relaxin
protein, the predominant form of relaxin in mice (Zhao et al,
1999), which has been found to be expressed in the skin
(Bathgate et al, 2002). We have since demonstrated that
RLX/ mice undergo an age-related and pregnancy-re-
lated progression of fibrosis in several reproductive organs
(Zhao et al, 2000; Samuel et al, 2003c), the lung (Samuel
et al, 2003d), heart (Du et al, 2003; Samuel et al, 2004a) and
kidneys (Samuel et al, 2004b), leading to altered tissue
structure and function.
In this study, we used RLX/mice to examine the long-
term effects of relaxin deprivation on the structure of the
skin with the specific aim of determining whether the lack of
relaxin affects dermal collagen deposition, types and integ-
rity. We also investigated the use of magnetic resonance
imaging as a diagnostic tool to detect the onset of fibrosis in
these animals, in addition to the effects of relaxin treatment
in RLX-KO (knockout) mice with early and established forms
of dermal fibrosis. Our findings, combined with our previ-
ously published work, demonstrate that the relaxin-deficient
mouse is a model of progressive scleroderma.
Results
The effects of relaxin deﬁciency on dermal collagen
concentration and types A progressive increase in dermal
collagen concentration (determined by hydroxyproline anal-
ysis) was observed in biopsies from male RLX/ mice,
which was significantly higher than that measured in age-
matched RLXþ /þmice at 6 mo (by 40%, po0.05) and
12 mo (by 56%, po0.02) of age (Fig 1A). A similar but de-
layed trend was also observed in the dermis of female RLX/
 mice, resulting in a 30% increase (po0.02) in dermal col-
lagen concentration by 12 mo of age (Fig 1A), compared with
measurements from age-matched RLXþ /þ animals.
Type I collagen was the predominant form of mature
collagen in the skin of immature (1 mo) and adult (12 mo)
RLXþ /þ and RLX/ male and female mice (Fig 1B), rep-
resenting over 90% of the total collagen present. Type I
collagen was represented by monomers (a1(I) and a2(I)
subunits), dimers (b11: dimers of two a1(I) subunits; b12:
dimers of a1(I) and a2(I) monomers) and trimers (g) in the
dermis, whereas lower amounts of type III collagen (a1(III)
subunits) monomers were also detected. No significant dif-
ferences in types I or III collagen were detected in the skin of
immature RLXþ /þ versus RLX/ animals, as determined
by densitometric studies (Fig 1B). Marked increases, however,
in types I (po0.01) and III (po0.01) collagen were observed in
12 mo old RLX/ mice, compared with that detected from
age-matched RLXþ /þ animals (Fig 1B), consistent with the
hydroxyproline data (Fig 1A). An identical trend was observed
in both male and female mice (data not shown).
The effects of relaxin deﬁciency on skin histology The
dermis of Masson trichrome-stained skin sections from 1
mo (Fig 2A), 3 mo (Fig 2C), 6 mo (Fig 2E), and 14 mo (Fig 2G)
old RLXþ /þ mice consisted of an extracellular matrix of
collagen fiber bundles (blue staining) that were packed as
parallel arrays of fibrils. The collagen fibers of adult mice
became more densely packed with age, contributing to in-
creased skin thickening. Beneath the dermis, the subcuta-
neous tissue (hypodermis) containing fat and adipose cells
Figure 1
Effect of relaxin deficiency on dermal
collagen concentration and types. Col-
lagen concentration (collagen content as
a percentage of the dry weight tissue)
was determined from 12 mm skin biop-
sies from ageing male and female
relaxin normal (RLXþ /þ ) and deficient
(RLX/) mice (A). The numbers in pa-
rentheses represent the number of sam-
ples analyzed per group. po0.05 and
po0.02, when compared with corre-
sponding values from age-matched
RLXþ /þ mice. The types of maturely
cross-linked (pepsin-digested) collagen
in the dermis of ageing male RLXþ /þ
and RLX/ mice was determined by
sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) (B), us-
ing delayed reduction of the disulfide
bonds with 10% b-mercaptoethanol.
Shown is a representative gel of two in-
dividual pepsin digests from the skin of
1 and 12 mo old male RLXþ /þ and
RLX/ mice. Pepsin digests from four
to five individual animals per group and
time point were analyzed by SDS-PAGE.
Densitometric analysis of the type I (a1(I)
and a2(1) chains) and type III (a1(III)
chain) collagen chains was also per-
formed on n¼4–5 samples per group
and time point. po0.01, when com-
pared with corresponding values from
age-matched RLXþ /þ mice. An iden-
tical trend was also observed in samples
from female mice (data not shown).
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also appeared to increase in thickness by 6 mo of age
(Fig 2E), but lost much of its integrity by 14 mo of age (Fig
2G). The skin of RLX/ mice was progressively thickened
with time, caused by increased fibrosis throughout the de-
rmis, which also appeared to supersede the hypodermis.
Dermal fibrosis was evident in RLX/ mice by 1 mo (Fig
2B) of age and the density of collagen fibers contributing to
this fibrosis was markedly increased by 3 mo (Fig 2D), 6 mo
(Fig 2F), and 14 mo (Fig 2H). The epidermis of RLX/mice
appeared normal, as compared with that observed in
RLXþ /þ animals.
The effects of relaxin deﬁciency on dermal ﬁbroblast-
induced collagen secretion and deposition, in vitro Der-
mal fibroblasts from RLX/ mice were able to deposit
38% more collagen (po0.05) into the cell matrix, over a 7-d
culture period (Fig 3A), as compared to that measured from
Figure 2
Effects of relaxin deficiency on skin histology. Masson trichrome
staining was used to identify changes in collagen (matrix) within the
dermis of 1 mo old (A, B), 3 mo old (C, D), 6 mo old (E, F) and 14 mo old
(G, H) relaxin normal (RLXþ /þ ) (A, C, E, G) and relaxin-deficient
(RLX/) (B, D, F, H) male mice. Shown in each figure is the epidermis
and dermis of the skin, the underlying subcutaneous (hypodermis) tis-
sue and muscle. Scale bar¼0.1 mm.
Figure3
Effects of relaxin deficiency on dermal collagen synthesis and
deposition, in vitro. Collagen deposition into the cell matrix was
determined from dermal fibroblasts, derived from relaxin normal
(RLXþ /þ ) and relaxin-deficient (RLX/) mice, after 7 d in culture
(A). Numbers in parentheses represent number of separate cultures
grown from the skin of either RLXþ /þ or RLX/ mice. po0.05
versus corresponding value from RLXþ /þ mice. Biosynthetically la-
belled interstitial collagen synthesis and secretion was also measured
from human dermal fibroblasts after short-term or long-term exposure
to recombinant human gene-2 (H2) relaxin (B). Cells were either treated
with media alone (lane 1), H2 relaxin alone (10 ng per mL; lane 2),
transforming growth factor (TGF)-b alone (1 ng per mL; lane 3) or TGF-b
and H2 relaxin (lane 4) for 72-h in culture. Cells were also treated with
media alone for 20 d (lane 5); TGF-b (1 ng per mL) for 3 d followed by
media for 17 d (lane 6); TGF-b and H2 relaxin (10 ng per mL) for 3 d
followed by media for 17 d (lane 7); TGF-b for 3 d, H2 relaxin for 3 d and
then media for 14 d (lane 8); or TGF-b for 3 d followed by H2 relaxin for
17 d of culture (lane 9). Densitometry of the interstitial collagen bands
was performed and presented as a ratio of the 3 and 20 d untreated
control samples, respectively, which were expressed as 1.0.
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skin fibroblasts of age-matched RLXþ /þ animals, consist-
ent with the age-related increase in dermal fibrosis meas-
ured in RLX/ mice, in vivo.
Collagen secretion was markedly up-regulated by TGF-b
treatment of human dermal fibroblasts (HDF), over a 3-d
culture period (Fig 3B, lane 3), by 4–5-fold of that measured
in untreated cultures (Fig 3B, lane 1) over the same time. In
comparison, recombinant human gene-2 (H2) relaxin treat-
ment of HDF only had a modest effect on collagen secretion
(Fig 3B, lane 2), but was able to clearly downregulate the
TGF-b-induced effects on collagen synthesis by up to 50%,
over 3 d in culture (Fig 3B, lane 4), consistent with previous
findings (Unemori and Amento, 1990). Similar findings were
also obtained from a separate experiment, using the same
culture conditions.
Collagen secretion was still increased by 60%–70%,
when HDF were treated with TGF-b for 3 d, then removed
for 17 d (Fig 3B, lane 6), as compared with that measured
from HDF treated with media alone over 20 d (Fig 3B, lane
5). Collagen secretion was further increased when TGF-b-
stimulated HDF were either co-incubated with recombinant
H2 relaxin for 3 d of culture (Fig 3B, lane 7) or with H2 relaxin
for 3 d after stimulation (Fig 3B, lane 8), before being with-
drawn for a further 7–10 (data not shown) or 14–17 d of
culture, respectively. In contrast, collagen synthesis and
secretion were markedly inhibited by up to 50%, when HDF
were stimulated with TGF-b for 3 d, followed by continuous
exposure to recombinant H2 relaxin for 10 (data not shown)
or 17 d (Fig 3B, lane 9). Similar findings were also obtained
from a separate experiment, using the same culture con-
ditions. These findings indicated that (i) collagen synthesis,
pre-stimulated by a major pro-fibrotic factor, could only be
inhibited by relaxin, when continuously exposed to human
dermal fibroblasts, and (ii) removal of relaxin from human
dermal fibroblast cultures, after short-term exposure, led to
an increase in the collagen synthetic rate.
The effects of relaxin treatment on the skin of RLX/
mice At 6 mo of age (when dermal fibrosis was first ap-
parent by histology and hydroxyproline analysis), adminis-
tration of H2 relaxin to RLX/ mice resulted in the
significant reversal of dermal collagen deposition back to
levels measured in RLXþ /þ animals (Fig 4A). Histologically,
a marked decrease in collagen staining was observed in the
dermis of H2 relaxin-treated mice (Fig 4F), resulting from
less abundant collagen fibers that were not as tightly
packed, compared to the level of staining observed in un-
treated RLX/ mice (Fig 4D). At 12 mo of age (when der-
mal fibrosis was well established), H2 relaxin treatment of
RLX/ mice had no significant effects on dermal collagen
concentration (Fig 4A) or structure over a 2 wk period, as
compared with that measured in untreated and vehicle-
treated RLX/ mice.
Skin sections from 6 mo old RLXþ /þ mice (Fig 4C)
could be separated into three distinct regions, by magnetic
resonance imaging (MRI): a striated lighter gray region
(which corresponded to the upper part of the dermis con-
taining hair follicles, surrounded by connective tissue/col-
lagen sheaths (see Fig 4B)); a darker gray region (which
corresponded to the lower part of the dermis, containing
connective tissue/collagen); and a distinct light (white)
region (which corresponded to the subcutaneous tissue/
hypodermis containing adipose cells and fat). MRI scanning
of skin sections from 6 mo old RLX/ mice (Fig 4E) also
revealed the two regions of the dermis. These sections,
however, lacked the same intensity of the hypodermal re-
gion, consistent with Masson trichrome staining of the tis-
sue (Fig 4D), which demonstrated increased collagen and
decreased adipose tissue in this region of RLX/ mice. A
reduced intensity of the striation pattern of the lighter gray
region of these sections (Fig 4E) was also consistent with
increased collagen accumulation around the hair follicles.
H2 relaxin treatment of RLX/ mice resulted in the in-
creased intensity of the hypodermal layer and the striations
in the upper dermal layer (Fig 4G), consistent with the de-
crease in collagen staining that was observed by Masson
trichrome staining of sequential sections (Fig 4F). Skin sec-
tions from 12 mo old RLXþ /þ mice (Fig 4H) appeared
thinner than those from 6 mo old RLXþ /þ animals (Fig 4C),
hence, the dermal and hypodermal layers were detected,
but less well resolved, due to limited image resolution. In
contrast, skin sections from 12 mo old RLX/mice (Fig 4I)
were much thicker than their RLXþ /þ counterparts (Fig
4H) and lacked the clarity and intensity of the hypodermal
layer, most likely due to the increased collagen that had
superseded this layer.
A marked increase (po0.01) in fibroblast differentiation
(detected by a-smooth muscle actin (a-SMA); by 2.5–3-fold)
was observed in skin biopsies from 6 mo old untreated
RLX/ mice, compared with that measured in RLXþ /þ
mice (Fig 4J). H2 relaxin treatment of RLX/ mice was
able to normalize a-SMA expression (po0.01 vs levels from
untreated RLX/ mice), to that observed in RLXþ /þ
mice (Fig 4J), consistent with its ability to decrease collagen
concentration (Fig 4A) and staining (Fig 4F).
Discussion
In this study, we demonstrate that mice lacking the relaxin
gene over a lifetime, which encodes the major stored and
circulating form of relaxin, develop an age-related progres-
sion of dermal fibrosis and thickening. The dermis of male
and female RLX/ mice was associated with marked in-
creases in interstitial collagen over time, from as early as 1
mo of age. Dermal fibroblasts from RLX/ mice were also
shown to deposit increased collagen into the cell matrix in
vitro. Recombinant H2 relaxin treatment of RLX/ mice
resulted in the complete reversal of dermal fibrosis, when
applied to early stages of disease, but was ineffective when
applied to more established stages of dermal scarring over
a 2 wk treatment period. Relaxin was able to markedly in-
hibit TGF-b-induced collagen synthesis and secretion in
vitro, only when continuously exposed to human dermal
fibroblasts, whereas collagen secretion was again elevated
when relaxin was removed from cell cultures, after short-
term exposure. Furthermore, MRI scanning of skin biopsies
from RLXþ /þ and RLX/ mice treated with or without
H2 relaxin demonstrated a number of structural changes
within the skin, which correlated to changes observed by
histology. These combined findings support our previous
observations that relaxin is a naturally occurring inhibitor of
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collagen accumulation (in several organs including the skin)
in vivo and in vitro, by altering key matrix molecules, matrix
degrading enzymes and growth factors. Relaxin-null mice
offer the first direct evidence that links relaxin to a gener-
alized alteration of collagen turnover in normal skin.
In addition to the findings presented in this study, we had
previously demonstrated that RLX/ mice undergo an
age-related progression of interstitial fibrosis in the lung
(Samuel et al, 2003d), heart (Du et al, 2003), and kidneys
(Samuel et al, 2004b), leading to organ damage and dys-
function. The lungs of RLX/ mice were associated with
marked increases in collagen content and concentration,
resulting in altered alveolar structure, lung function and in-
creased bronchiole epithelium thickening (Samuel et al,
2003d). The heart of RLX/mice underwent an increase in
atrial hypertrophy, impeded left ventricular (LV) diastolic
filling and venous return, which was attributed to prog-
ressive increases in LV collagen content and ventricular
chamber stiffness (Du et al, 2003). The kidneys of ageing
RLX/ mice were also associated with focal increases in
Figure 4
Effects of recombinant human gene-2 (H2) relaxin treatment on the dermis of relaxin deficient mice. Collagen concentration was determined
from the skin of relaxin normal (RLXþ /þ ) mice, untreated relaxin-deficient (RLX/) mice and RLX/ mice treated with either vehicle alone or
with 0.5 mg per kg per day recombinant H2 relaxin (over 14 d), at 6 and 12 mo of age (A). Numbers in parentheses represent the number of samples
analyzed per group. po0.01, when compared with corresponding values from untreated and vehicle-treated RLX/ mice. Masson trichrome
staining of collagen within the dermis and magnetic resonance imaging (MRI) scans of two representative skin sections from separate 6 mo old
RLXþ /þ (B and C, respectively), untreated RLX/ (D and E, respectively) and recombinant H2 relaxin-treated RLX/ (F and G, respectively)
mice were used to detect and compare changes in skin architecture, before and after relaxin treatment. MRI scans of two representative skin
sections from 12 mo old RLXþ /þ (H) and RLX/ (I) mice were also used for comparative analysis. Scale bar¼0.1 mm. Western blotting of a-
smooth muscle actin (a-SMA) (J), a marker for myofibroblast accumulation, was conducted on protein extracts (10 mg per sample), from the skin of 6
mo old RLXþ /þ (lanes 1–2), RLX/ (lanes 3–4) and H2 relaxin-treated RLX/ (lanes 5–7) mice. Shown is a representative blot of n¼3–4
samples per group. Western blots of the housekeeping protein, b-tubulin was also performed to demonstrate equal loading of the protein samples,
whereas densitometry scanning of the mean  SEM optical density values of a-SMA are also shown (J). po0.01 versus corresponding values
from RLXþ /þ mice; ##po0.01 versus corresponding values from untreated RLX/ mice.
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interstitial fibrosis and a more general diffuse increase in
glomerulosclerosis, resulting in increased cortical thicken-
ing and reduced renal function (Samuel et al, 2004b). Ad-
ditionally, small renal arteries isolated from RLX/ animals
were less compliant and had significantly reduced my-
ogenic reactivity, as compared with renal arteries from
RLXþ /þ mice (personal communication: Dr Jacqueline
Novak, Dr Laura J. Parry, and Professor Kirk P. Conrad).
These combined findings demonstrate that RLX/ mice
undergo certain symptoms of systemic sclerosis, charac-
terized by increased fibrosis of the dermis and internal or-
gans, in addition to altered blood vessel integrity. To
date however, the inflammatory and immunological defi-
ciencies that contribute to scleroderma in this model are yet
to be demonstrated. Like several other animal models of
scleroderma involving induced and/or spontaneous sys-
tems (Bocchieri and Jiminez, 1990), the RLX/ mouse
only mimics certain aspects of scleroderma, but along with
all other available models, does not mimic the entire spec-
trum of this complex disorder. The RLX/ mouse can also
be compared to the most extensively used model of
scleroderma, the TSK/þ mutant mouse, which also
demonstrates fibrosis of the skin and internal organs but
is absent of inflammatory, immunological, vascular, gastro-
intestinal and articular involvement (Bocchieri and Jiminez,
1990).
Although scleroderma affects women more than men,
our findings in RLX/ mice demonstrated that male mice
developed a more rapid progression of dermal fibrosis and
also consistently developed an age-related progression of
pulmonary, cardiac and renal fibrosis. Whereas female
RLX/ mice developed fibrosis in some organs (skin,
lung), the severity and onset of disease was less pro-
nounced and delayed, respectively, whereas in other organs
(heart, kidney), they did not demonstrate any changes in
collagen accumulation, as compared to that measured in
RLXþ /þ animals. Thus, the phenotype differences ob-
served between male and female RLX/ mice may be the
result of using a genetically modified model, which have
been reported to cause some organs to display male gen-
der-restricted or -biased phenotypes (Du, 2004). Alterna-
tively, the presence of androgens in males may have
detrimental consequences on the progression of fibrosis
or other female-specific hormones or sex steroids may be
compensating for the absence of relaxin in female RLX/
mice. This is consistent with the fact that hormones, such
as estrogen, have a profound effect on the ageing skin
(Sator et al, 2004) and are known to increase collagen
biosynthesis by human skin fibroblasts (Surazynski et al,
2003).
Remarkably, recombinant H2 relaxin treatment of 6 mo
old RLX/ mice (with an early onset of dermal fibrosis)
resulted in the significant reduction and normalization of
dermal fibroblast function and collagen concentration to
that observed in age-matched RLXþ /þ mice. In contrast,
H2 relaxin had no significant effects on established dermal
fibrosis when administered to 12 mo old RLX/ mice,
despite its ability to significantly inhibit established pulmo-
nary, renal and cardiac fibrosis by 40%–70% at this time
point (Samuel et al, 2003d, 2004a, 2004b). The increased
viscosity of the dermis, compared to the other organs and/
or permanent damage to the internal structure of the skin,
most likely explains why relaxin may not been responsive at
this time point. These findings demonstrate that there is a
narrow window within which relaxin can successfully be
used as an anti-fibrotic therapy for dermal scarring. These
findings are of particular importance, given that clinical trials
on recombinant H2 relaxin’s effects on systemic sclerosis
recently demonstrated that relaxin was biologically active
and well tolerated in humans (Erikson and Unemori, 2001).
Although relaxin treatment benefited only some individuals,
the primary efficacy of relaxin as an antifibrotic agent was
not met in phase II/III of these trials, due to the addition of
several patients with end-stage scleroderma that appeared
to be untreatable. Our studies also demonstrate that the
potency and efficacy of relaxin as an antifibrotic therapy is
diminished, when applied to more severe stages of dermal
fibrosis.
Relaxin has been shown to act at multiple levels to de-
crease collagen accumulation in several organs, including
the skin (Unemori and Amento, 1990; Unemori et al, 1993).
Although limited studies have demonstrated that relaxin is
able to bind to endothelial cells (Quattrone et al, 2004) and
adipocytes (Bani-Sacchi et al, 1987), our studies demon-
strate that relaxin acts directly on dermal fibroblasts to in-
hibit their differentition, which would otherwise lead to the
over-production of collagen (and other matrix proteins) in
the skin. This is consistent with the finding that H2-relaxin
treatment of RLX/ mice inhibited dermal collagen se-
cretion and deposition to levels observed in RLXþ /þmice.
Notably, the re-appearance of the hypodermal layer, post-
H2 relaxin treatment, was most likely due to the reduction of
myofibroblast and collagen expression, rather than to
direct affects of relaxin on adipocytes and/or other cell
types.
In this study, we also employed MRI as a potential non-
invasive diagnostic tool to detect changes in the skin ar-
chitecture that were associated with dermal fibrosis. For
these studies, we used fixed samples from 6 and 12 mo old
mice. MRI scans of skin biopsies from RLXþ /þ mice were
able to detect distinct regions of the skin, which corre-
sponded to the dermal and hypodermal layers of the tissue.
The distinctive feature of the MRI scans was the detection
of the hypodermal layer (containing adipose tissue/fat),
which appeared as a white/light band with high intensity. In
RLX/ mice, the increased fibrosis was characterized by
the loss of intensity of this white band and a progressive
increase in dermal thickening with age, which matched
what was observed by histology. Importantly, in biopsies
from recombinant H2 relaxin-treated (6 mo old) mice, the
restoration of this white band (hypodermis) and the striat-
ions within the upper dermal layer to that observed in bi-
opsies from RLXþ /þ mice was consistent with histological
analysis of the tissue. These findings suggested that the
MRI may be used a potential diagnostic tool to detect the
onset of dermal fibrosis in animals and humans, but requires
further optimization. Scanning the progression of disease in
live animals is also the subject of future investigation.
In conclusion, we have demonstrated that the removal of
the relaxin gene from mice resulted in a progressive build-
up of collagen in the skin, resulting in dermal fibrosis and
thickening. Furthermore, relaxin may provide an important
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means to regulate excessive collagen deposition in skin
disorders associated with or characterized by fibrosis.
Materials and Methods
Reagents Recombinant H2 relaxin was generously provided by
BAS Medical (San Mateo, California) and is bioactive in mice
(Unemori et al, 1996; Samuel et al, 2003d, 2004a, b).
Animals All male and female relaxin wild-type (RLXþ /þ ) and
RLX/ mice used in this study were age-matched litter-mates,
generated from RLXþ / (C57Blk6J  129SV) parents (Zhao et al,
1999). The animals were housed in a controlled environment and
maintained as described previously (Samuel et al, 2003d; 2004b).
These experiments were approved by the Howard Florey Institute
and Molecular Medicine Research Institute Animal Experimental
Ethics Committees, which adhere to the Australian and NIH Codes
of Practice, respectively, for the care and use of laboratory animals
for scientific purposes.
Tissue collection Male and female RLXþ /þ and RLX/ mice
were obtained at 1, 6, and 12 mo of age, whereas additional mice
were obtained at 3 and 14 mo of age (n¼ 8–12 per genotype,
gender, and age-group). All mice were weighed, before being eu-
thanized and shaved for tissue collection. Skin biopsies (12 mm in
diameter) were taken from the same location, off the back of each
mouse for analysis. Tissues were then either stored at 801C for
hydroxyproline, SDS-PAGE, and Western blot analyses or fixed in
10% formalin for histological and MRI analysis.
Hydroxyproline analysis of skin biopsies The collected skin bi-
opsies from male and female RLXþ /þ and RLX/ mice were
lyophilized to dry weight, before being re-hydrated, hydrolyzed
with 6 M hydrochloric acid, and treated as described previously
(Samuel et al, 1996). Hydroxyproline values were then converted to
collagen content by multiplying by a factor of 6.94 (Gallop and Paz,
1975), whereas collagen concentration was calculated by dividing
the collagen content by the tissue dry weight.
Determination of collagen types in the skin Skin biopsies from
male and female 1 and 12 mo old RLXþ /þ and RLX/ mice
(n¼ 4–5 per genotype and gender) were separated and finely diced
in the presence of liquid nitrogen. The pepsin-digested collagen
was then extracted and analyzed by SDS-PAGE, as described
before (Samuel et al, 1996). Densitometric analysis of the interstitial
collagen chains was then performed for quantitatative studies, as
described before (Samuel et al, 2003b).
Histology of skin biopsies Fixed skin biopsies from male and
female 1, 3, 6, and 14 mo old RLXþ /þ and RLX/ mice (n¼ 4
per genotype) were washed, processed, paraffin embedded, and
cut as described before (Samuel et al, 2004b). The sections were
cut such that the epidermis, dermis, underlying subcutaneous
(adipose) tissue and muscle could be observed. Serial sections
from each tissue were stained with hematoxylin and eosin (H&E)
and for collagen, with the Masson trichrome stain. The stained
slides were viewed and analyzed as described previously (Samuel
et al, 2004b). Several tissue sections were screened with each
stain and a representative slide chosen for figure presentation.
Human recombinant relaxin treatment of RLX/ mice 5.5 mo
(n¼ 8) and 11.5 mo old (n¼ 12) male RLX/ mice, with early and
established dermal fibrosis, respectively, were anesthetized and
subjected to subcutaneous implantation of osmotic mini-pumps
(model 2002; Alza, Cupertino, California) as described previously
(Samuel et al, 2003d). The osmotic mini-pumps were loaded with
either a 20 mM sodium acetate buffer, pH 5.0 (vehicle; n¼ 10) or
0.5 mg per kg per day (20 mg per day) recombinant H2 relaxin (in
sodium acetate buffer; n¼ 10), which were maintained for 14 d.
The dose of recombinant H2 relaxin added was previously shown
to produce circulating levels of 20–40 ng per mL after 14 d of
treatment and to successfully treat cardiac, pulmonary, and renal
fibrosis in 12 mo old, male RLX/ mice (Samuel et al, 2003d;
2004a, b). After 14 d, the animals were euthanized and skin biop-
sies collected for various analyses.
MRI of mouse skin Fixed skin tissues from male 6 and 12 mo old
RLXþ /þ and RLX/ mice and from 5.5 mo old RLX/ mice
treated with recombinant H2 relaxin for 14 d (n¼ 3–4 per group)
were scanned with a 4.7T MR BIOSPEC system (Bruker, Germany).
Multiple skin samples were placed on a specially designed sample
holder with multi-layer plastic sheets. A total number of 10 samples
could be scanned simultaneously using a T1-weighted spin-echo
sequence with TR/TE equal to 800/26.1 ms and scanning time
equal to 14 h 34 min for 128 NEX. Sixteen sagittal slices were
acquired providing cross-sectional view of all skin samples in each
image. A high-resolution imaging matrix of 512  512 with a field of
view (FOV) of 20 mm along the frequency direction, 13.5 mm along
the phase encoding direction and 0.5 mm slice thickness was
used. The phase encoding direction was perpendicular to the skin
to avoid a chemical-shift effect of the subcutaneous (adipose) layer
underneath the skin (dermis). The image resolution was 26 and 39
mm in a perpendicular and parallel direction to the skin layer, re-
spectively.
Western blotting Protein extracts from skin biopsies of 6 mo
old male RLXþ /þ , untreated RLX/, and H2 relaxin-treated
RLX/ mice (n¼ 3–4 per group) were analyzed by Western blot-
ting, for the detection of a-SMA (a marker for fibroblast differen-
tiation), as previously described (Samuel et al, 2004a). A
monoclonal antibody to a-SMA (M0851, 1:1000 dilution) was com-
mercially purchased (Dako Corporation, Carpinteria, California),
whereas a monoclonal antibody to the housekeeping protein, b-
tubulin (kindly provided by Dr Zhonglin Chai, Baker Heart Research
Institute, Victoria, Australia) was also used to demonstrate equal
loading of the protein samples. Densitometric analysis of a-SMA
was then performed as described above.
Cell culture
Mouse dermal ﬁbroblast cultures To investigate the effects of re-
laxin-deficiency on fibroblast-induced collagen deposition in vitro,
dermal fibroblasts from the skin of adult (4 mo old) RLXþ /þ and
RLX/ mice, were isolated using standard collagenase digestion
(Unemori and Amento, 1990) and used between passages two and
five for these studies. The cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) containing Hams F12 medium
(1:1 ratio), 15% fetal calf serum and the antibiotics, penicillin (75 U
per mL) and streptomycin (75 mg per mL). Five separate fibroblast
cultures from RLXþ /þ mice and four separate cultures from
RLX/ mice were plated at a density of 2  106 cells per 60 mm2
dish and grown for a 7 d period, before the media discarded and
the cell layer collected and analyzed for hydroxyproline content (as
a measure of the deposited collagen into the cell layer), as de-
scribed above.
HDF cultures To investigate the short-term and long-term effects
of relaxin on collagen secretion in vitro, human dermal fibroblasts
(which were generously provided by Dr Elaine Unemori; Connetics
Corporation, Palo Alto, California), were maintained in DMEM, as
described before (Unemori and Amento, 1990) and used between
passages ten and 14. For short-term studies, the fibroblasts
(1  105 cells per well; 24-well plate) were either incubated with
media alone, recombinant H2 relaxin (10 ng per mL) alone, TGF-b
(1 ng per mL) alone or recombinant H2 relaxin (10 ng per mL), and
TGF-b (1 ng per mL) for a 72 h culture period. For longer-term
studies, fibroblasts were incubated with (i) media alone for 20 d, (ii)
TGF-b (1 ng per mL) for 3 d, then medium for 17 d, (iii) TGF-b (1 ng
per mL), and recombinant H2 relaxin (10 ng per mL) for 3 d, then
medium for 17 d, (iv) TGF-b (1 ng per mL) for 3 d followed by
recombinant H2 relaxin (10 ng per mL) for 3 d, then media for 14 d,
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or (v) TGF-b (1 ng per mL) for 3 d followed by recombinant H2
relaxin (10 ng per mL) treatment for 17 d. Collagen biosynthesis
was then determined by labelling cells with [3H]-proline (25 mCi per
mL) as described before (Unemori and Amento, 1990), and quan-
tified by densitometry scanning of the a1(I)/a1(III) collagen bands
from each sample, using Kodak (Rochester, New York) 1D imaging
software. The data from each treatment group was presented as a
ratio of the 3 and 20 d untreated control samples, respectively,
which were expressed as 1.0.
Statistical analysis The results were analyzed using a one-way
ANOVA, using the Newman–Keuls test for multiple comparisons
between groups. All data in this paper are presented as the
mean  SEM, with po0.05 described as statistically significant.
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